Sacituzumab govitecan-hziy (Elahere) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), indicated for the treatment of FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Due to its specific indications and strict medication requirements, attention must be paid to legal purchasing channels, medication safety, and authentication of authenticity when purchasing.
How to Purchase Sacituzumab Govitecan-hziy (Elahere)
Overseas Purchase
Patients may choose to consult and purchase the drug at hospital pharmacies or authorized pharmacies in countries/regions where sacituzumab govitecan-hziy has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase through Medical Service Institutions
Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and offer professional consultation and guidance.
Precautions for Purchasing Sacituzumab Govitecan-hziy (Elahere)
Strictly Follow Medical Advice
The recommended dose is 6 mg/kg (calculated based on adjusted ideal body weight), administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity occurs.
Pre-treatment with glucocorticoids, antihistamines, antipyretics, and antiemetics is required before infusion. In addition, topical ocular corticosteroids and lubricating eye drops should be used to prevent ocular toxicity.
Contraindications and High-Risk Populations
Ocular diseases: Patients with active corneal disease or ocular conditions requiring continuous treatment should use the drug with caution.
Hepatic impairment: The drug is contraindicated in patients with moderate to severe hepatic impairment (total bilirubin > 1.5 × upper limit of normal [ULN]).
Pregnancy and lactation:
The drug is contraindicated in pregnant women.
Women of childbearing age must use effective contraception during treatment and for 7 months after the last dose.
Lactating women should discontinue breastfeeding and resume it 1 month after stopping the drug.
Monitoring for Adverse Reactions
Common adverse reactions include blurred vision, corneal lesions, fatigue, nausea, diarrhea, and peripheral neuropathy.
If symptoms such as dyspnea (which may indicate pneumonia) or severe vision loss occur, immediate medical attention is required.
How to Authenticate Sacituzumab Govitecan-hziy (Elahere)
Packaging and Appearance
The drug is supplied as a single-dose vial with a specification of 100 mg/20 mL (5 mg/mL), and the solution is colorless to slightly opalescent.
The label should include manufacturer information (ImmunoGen, Inc.), batch number, expiration date, and FDA approval number.
Package Insert and Label
Authentic products are accompanied by an English package insert that details ingredients, indications, contraindications, and adverse reactions.
Counterfeit products may have typographical errors or missing content.
Post-Medication Verification
Before the first use, the pharmaceutical department of the hospital can be consulted to help confirm the physical properties of the drug.
Abnormal adverse reactions (e.g., unforeseen severe ocular toxicity) may indicate the risk of counterfeit drugs.
